12 Best Blue Chip Stocks to Buy Under $100

Page 3 of 11

9. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holdings: 70

Stock Price as of January 24: $59.67

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical giant focused on innovative therapies for oncology, cardiovascular, and immunological conditions. The company’s portfolio includes key drugs such as Opdivo and Eliquis, which drive significant revenue growth. Bristol-Myers Squibb Company’s (NYSE:BMY) partnerships with healthcare providers, its global presence, and its commitment to R&D make it a trusted name in the pharmaceutical industry.

Bristol-Myers Squibb Company (NYSE:BMY) is strategically advancing its pipeline by focusing on transformational medicines in areas where it holds a competitive advantage. This includes enhancing its oncology portfolio through acquisitions such as RayzeBio, which grants access to radiopharmaceuticals and is one of the fastest-growing platforms in solid tumor oncology. In immunology, the company is pursuing groundbreaking treatments designed to reset the immune system, exemplified by its CD19 NEX-T program for autoimmune diseases.

Additionally, Bristol-Myers Squibb Company (NYSE:BMY) is leveraging technology and artificial intelligence (AI) to accelerate innovation and improve the success rate of its research and development efforts. The company is using AI to enhance drug discovery, optimize clinical trial design, and improve operational efficiency. By incorporating advanced technologies, the company aims to bring new medicines to market more quickly and efficiently, driving sustainable growth and delivering value to patients and shareholders alike.

Page 3 of 11